Karolinska Institutet
Browse
DOCUMENT
AAM_Breast cancer genetic risk profile.pdf (391.02 kB)
DOCUMENT
Supplementary Table S1-3_Li.pdf (199.44 kB)
1/0
2 files

Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancers.

BACKGROUND: Polygenic risk profiles computed from multiple common susceptibility alleles for breast cancer have been shown to identify women at different levels of breast cancer risk. We evaluated whether this genetic risk stratification can also be applied to discriminate between screen-detected and interval cancers, which are usually associated with clinicopathological and survival differences. PATIENTS AND METHODS: A 77 single-nucleotide polymorphism polygenic risk score (PRS) was constructed for breast cancer overall and by estrogen receptor (ER) status. PRS was inspected as a continuous (per standard deviation increment) variable in a case-only design. Modification of the PRS by mammographic density was evaluated by fitting an additional interaction term. RESULTS: PRS weighted by breast cancer overall estimates was found to be differentially associated with 1865 screen-detected and 782 interval cancers in the LIBRO-1 study {age-adjusted odds ratio (OR)perSD [95% confidence interval (CI)] 0.91 [0.83-0.99], P = 0.023}. The association was found to be more significant for PRS weighted by ER-positive breast cancer estimates [ORperSD = 0.90 (0.82-0.98), P = 0.011]. This result was corroborated by two independent studies [combined ORperSD = 0.87 (0.76-1.00), P = 0.058] with no evidence of heterogeneity. When enriched for 'true' interval cancers among nondense breasts, the difference in the association with PRS in screen-detected and interval cancers became more pronounced [ORperSD = 0.74 (0.62-0.89), P = 0.001], with a significant interaction effect between PRS and mammographic density (Pinteraction = 0.017). CONCLUSION: To our knowledge, this is the first report looking into the genetic differences between screen-detected and interval cancers. It is an affirmation that the two types of breast cancer may have unique underlying biology.

Funding

The Natural history of breast cancer - Predicting high risk for metastatic disease and insensitivity to endocrine therapy in hormonal receptor positive patients : Swedish Research Council | 2011-06857_VR

History

File version

  • Accepted manuscript

Publication status

Published

Sub type

Article

Journal

Ann Oncol

ISSN

0923-7534

eISSN

1569-8041

Volume

26

Issue

3

Pagination

517-522

Language

  • eng

Original self archiving date

2020-04-17

Usage metrics

    Articles

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC